SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,636.81 (-2.88%)
DOW   29,239.87 (-2.30%)
QQQ   269.19 (-3.78%)
AAPL   140.08 (-3.68%)
MSFT   234.14 (-5.13%)
META   132.99 (-4.37%)
GOOGL   98.46 (-2.92%)
AMZN   114.60 (-4.74%)
TSLA   223.02 (-6.35%)
NVDA   121.25 (-7.65%)
NIO   13.70 (-7.24%)
BABA   80.90 (-4.06%)
AMD   59.22 (-12.72%)
T   15.02 (-1.96%)
MU   53.03 (-2.91%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.19 (-3.07%)
DIS   96.67 (-3.37%)
AMC   6.46 (-9.27%)
PYPL   89.97 (-4.71%)
PFE   42.14 (-2.20%)
NFLX   227.67 (-5.15%)
S&P 500   3,636.81 (-2.88%)
DOW   29,239.87 (-2.30%)
QQQ   269.19 (-3.78%)
AAPL   140.08 (-3.68%)
MSFT   234.14 (-5.13%)
META   132.99 (-4.37%)
GOOGL   98.46 (-2.92%)
AMZN   114.60 (-4.74%)
TSLA   223.02 (-6.35%)
NVDA   121.25 (-7.65%)
NIO   13.70 (-7.24%)
BABA   80.90 (-4.06%)
AMD   59.22 (-12.72%)
T   15.02 (-1.96%)
MU   53.03 (-2.91%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.19 (-3.07%)
DIS   96.67 (-3.37%)
AMC   6.46 (-9.27%)
PYPL   89.97 (-4.71%)
PFE   42.14 (-2.20%)
NFLX   227.67 (-5.15%)
S&P 500   3,636.81 (-2.88%)
DOW   29,239.87 (-2.30%)
QQQ   269.19 (-3.78%)
AAPL   140.08 (-3.68%)
MSFT   234.14 (-5.13%)
META   132.99 (-4.37%)
GOOGL   98.46 (-2.92%)
AMZN   114.60 (-4.74%)
TSLA   223.02 (-6.35%)
NVDA   121.25 (-7.65%)
NIO   13.70 (-7.24%)
BABA   80.90 (-4.06%)
AMD   59.22 (-12.72%)
T   15.02 (-1.96%)
MU   53.03 (-2.91%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.19 (-3.07%)
DIS   96.67 (-3.37%)
AMC   6.46 (-9.27%)
PYPL   89.97 (-4.71%)
PFE   42.14 (-2.20%)
NFLX   227.67 (-5.15%)
S&P 500   3,636.81 (-2.88%)
DOW   29,239.87 (-2.30%)
QQQ   269.19 (-3.78%)
AAPL   140.08 (-3.68%)
MSFT   234.14 (-5.13%)
META   132.99 (-4.37%)
GOOGL   98.46 (-2.92%)
AMZN   114.60 (-4.74%)
TSLA   223.02 (-6.35%)
NVDA   121.25 (-7.65%)
NIO   13.70 (-7.24%)
BABA   80.90 (-4.06%)
AMD   59.22 (-12.72%)
T   15.02 (-1.96%)
MU   53.03 (-2.91%)
CGC   2.80 (-25.33%)
F   12.14 (-1.78%)
GE   64.19 (-3.07%)
DIS   96.67 (-3.37%)
AMC   6.46 (-9.27%)
PYPL   89.97 (-4.71%)
PFE   42.14 (-2.20%)
NFLX   227.67 (-5.15%)
NASDAQ:ALRN

Aileron Therapeutics - ALRN Stock Forecast, Price & News

$0.26
+0.01 (+4.00%)
(As of 10/7/2022 01:08 PM ET)
Add
Compare
Today's Range
$0.26
$0.26
50-Day Range
$0.14
$0.28
52-Week Range
$0.13
$1.03
Volume
700 shs
Average Volume
1.66 million shs
Market Capitalization
$23.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Aileron Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
1,053.8% Upside
$3.00 Price Target
Short Interest
Healthy
0.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.34) to ($0.26) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

589th out of 1,075 stocks

Pharmaceutical Preparations Industry

272nd out of 537 stocks

ALRN stock logo

About Aileron Therapeutics (NASDAQ:ALRN) Stock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update
See More Headlines
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Company Calendar

Last Earnings
8/15/2022
Today
10/07/2022
Next Earnings (Estimated)
11/11/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$1.00
Forecasted Upside/Downside
+1,053.8%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-26,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.48 per share

Miscellaneous

Free Float
87,645,000
Market Cap
$23.61 million
Optionable
Not Optionable
Beta
2.04

Key Executives

  • Dr. Manuel C. Aivado M.D. (Age 52)
    Ph.D., Pres, CEO & Director
    Comp: $912.38k
  • Ms. Susan L. Drexler CPA (Age 52)
    M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer
  • Dr. D. Allen Annis Ph.D. (Age 49)
    Sr. VP of Research













ALRN Stock - Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALRN, but not buy additional shares or sell existing shares.
View ALRN analyst ratings
or view top-rated stocks.

What is Aileron Therapeutics' stock price forecast for 2022?

3 equities research analysts have issued 12-month target prices for Aileron Therapeutics' stock. Their ALRN share price forecasts range from $1.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,100.0% from the stock's current price.
View analysts price targets for ALRN
or view top-rated stocks among Wall Street analysts.

How have ALRN shares performed in 2022?

Aileron Therapeutics' stock was trading at $0.5629 at the beginning of the year. Since then, ALRN stock has decreased by 55.6% and is now trading at $0.25.
View the best growth stocks for 2022 here
.

When is Aileron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ALRN earnings forecast
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings data on Monday, August, 15th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09).

What other stocks do shareholders of Aileron Therapeutics own?
When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

What is Aileron Therapeutics' stock symbol?

Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aileron Therapeutics' stock price today?

One share of ALRN stock can currently be purchased for approximately $0.25.

How much money does Aileron Therapeutics make?

Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $22.71 million. The company earns $-26,160,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.

How can I contact Aileron Therapeutics?

Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:ALRN) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.